Revenue - Schedule of Disaggregated Revenues (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Royalties, license and other revenues	[1]	$ 1,350	$ 1,357
Total revenues under collaborative agreements		8,149	7,588
Total revenues		9,499	8,945
Upfront License Fees [Member]
Disaggregation of Revenue [Line Items]
Total revenues under collaborative agreements	[2]	$ 8,149	$ 7,588

[1] Of the royalties, license and other revenues recognized each period, $30,000 and $87,000 was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively.

[2] All of the upfront license fee revenue recognized each period was included within deferred revenue as contract liabilities at the beginning of the period. This revenue originated from the $50.0 million upfront payment under the Roche Agreement.